PGC-1α agonism induces fetal hemoglobin and exerts antisickling effects in sickle cell disease
Science Advances · 2024
DOI: 10.1126/sciadv.adn8750 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2024. Verfasst von Yanan Sun und 13 weiteren Autor:innen. Beteiligte Einrichtung: Section of Hematology-Medical Oncology, Department of Medicine, Boston Medical Center, Boston University Chobanian & Avedisian School of Medicine, Bo…. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Fetal Hemoglobin, Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha, Antisickling Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NLM NIH HHS.
Abstract (Originalsprache)
Sickle cell disease is a growing health burden afflicting millions around the world. Clinical observation and laboratory studies have shown that the severity of sickle cell disease is ameliorated in individuals who have elevated levels of fetal hemoglobin. Additional pharmacologic agents to induce sufficient fetal hemoglobin to diminish clinical severity is an unmet medical need. We recently found that up-regulation of peroxisome proliferator–activated receptor γ coactivator-1α (PGC-1α) can induce fetal hemoglobin synthesis in human primary erythroblasts. Here, we report that a small molecule, SR-18292, increases PGC-1α leading to enhanced fetal hemoglobin expression in human erythroid cells, β-globin yeast artificial chromosome mice, and sickle cell disease mice. In SR-18292–treated sickle mice, sickled red blood cells are significantly reduced, and disease complications are alleviated. SR-18292, or agents in its class, could be a promising additional therapeutic for sickle cell disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Section of Hematology-Medical Oncology, Department of Medicine, Boston Medical Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.
- Single Cell Sequencing Core Facility, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.
- Imam Abdulrahman Bin Faisal University, Department of Clinical Biochemistry, Dammam, Saudi Arabia.
- Sargent College of Health and Rehabilitation Sciences, Boston University, Boston, MA, USA.
- Department of Pathology and Laboratory Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.
- Division of Computational Biomedicine, Department of Medicine, Boston Medical Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.
ORCID-Profile: Yanan Sun, Alawi Habara, Eric Fu, Yuriy O Alekseyev, Joshua D Campbell, Shuaiying Cui
Förderung
- NHLBI NIH HHS
- NLM NIH HHS
Zitieren
APA
Sun, Y., Benmhammed, H., Al Abdullatif, S., Habara, A., Fu, E., Brady, J., Williams, C., Ilinski, A., Sharma, A., Mahdaviani, K., Alekseyev, Y. O., Campbell, J. D., Steinberg, M. H., & Cui, S. (2024). PGC-1α agonism induces fetal hemoglobin and exerts antisickling effects in sickle cell disease. Science Advances. https://doi.org/10.1126/sciadv.adn8750
Vancouver
Sun Y, Benmhammed H, Al Abdullatif S, Habara A, Fu E, Brady J, et al. PGC-1α agonism induces fetal hemoglobin and exerts antisickling effects in sickle cell disease. Science Advances. 2024. doi:10.1126/sciadv.adn8750
BibTeX
@article{Sun2024,
author = {Sun, Yanan and Benmhammed, Hajar and Al Abdullatif, Salam and Habara, Alawi and Fu, Eric and Brady, Jordan and Williams, Christopher and Ilinski, Adrian and Sharma, Anusha and Mahdaviani, Kiana and Alekseyev, Yuriy O and Campbell, Joshua D and Steinberg, Martin H and Cui, Shuaiying},
title = {PGC-1α agonism induces fetal hemoglobin and exerts antisickling effects in sickle cell disease},
journal = {Science Advances},
year = {2024},
doi = {10.1126/sciadv.adn8750}
}
EUVIMED